Speratum
1 known investors
Find your way into Speratum
123 people in our graph share verified history with the Speratum team — schools, employers, funds. One of them is your warm intro.
Aravind Ratnamunlockedknows Christian Marín Müller · together at Florida Institute of Technology (overlapped)
×2knows the team · via Baylor College of Medicine
×7knows the team · via Weatherhead School of Management at Case Western Reserve University
×2knows the team · via Florida Institute of Technology
Speratum Biopharma develops RNA interference (RNAi) therapeutics for cancer and other hard-to-treat genetic diseases, using its proprietary NoPass RNAi design platform and Nano-In nanoparticle delivery system. Its lead candidate, NM-198, is based on the tumor-suppressor microRNA miR-198 and targets multiple oncogenic pathways in solid tumors.
Founders & leadership
CM
Christian Marín MüllerinFounderChristian Marín Müller holds a Ph.D. in Molecular Virology and Microbiology from Baylor College of Medicine and an MS in Entrepreneurial Biotechnology from Case Western Reserve University. He worked as a Post-Doctoral Associate in the Department of Surgery at Baylor College of Medicine, developing RNA interference therapeutics for cancer before founding Speratum in 2014, a pre-clinical stage biopharmaceutical company focused on RNAi-based cancer treatments using novel nanoparticle delivery systems.
Investors · 1
In the news
Frequently asked questions
- What does Speratum do?
- Speratum Biopharma develops RNA interference (RNAi) therapeutics for cancer and other hard-to-treat genetic diseases, using its proprietary NoPass RNAi design platform and Nano-In nanoparticle delivery system. Its lead candidate, NM-198, is based on the tumor-suppressor microRNA miR-198 and targets multiple oncogenic pathways in solid tumors.
- Who founded Speratum?
- Speratum was founded by Christian Marín Müller.
- Who are Speratum's investors?
- Speratum's investors include Carao Ventures.